These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10771644)

  • 1. [Ca2+ sensitizers].
    Endoh M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):859-67. PubMed ID: 10771644
    [No Abstract]   [Full Text] [Related]  

  • 2. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 3. [Calcium sensitizers--a new group of drugs that increase myocardium contractility].
    Laine M; Lehtonen L; Nieminen MS
    Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622
    [No Abstract]   [Full Text] [Related]  

  • 4. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 5. Levosimendan.
    Kamath SR; Jaykumar I; Matha S
    Indian Pediatr; 2009 Jul; 46(7):593-6. PubMed ID: 19638658
    [No Abstract]   [Full Text] [Related]  

  • 6. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 7. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 8. [Calcium mobilizers and calcium sensitizers].
    Arai M
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():417-22. PubMed ID: 22724240
    [No Abstract]   [Full Text] [Related]  

  • 9. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Endoh M
    Circ J; 2008 Dec; 72(12):1915-25. PubMed ID: 18981594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of SCH00013: a novel Ca2+ sensitizer.
    Endoh M; Sugawara H; Mineshima M
    Cardiovasc Drug Rev; 2001; 19(4):345-66. PubMed ID: 11830752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
    Endoh M
    Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure].
    Porcu M; Orrù P
    Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888
    [No Abstract]   [Full Text] [Related]  

  • 19. The case for levosimendan.
    De Keulenaer BL
    Crit Care Resusc; 2008 Sep; 10(3):180. PubMed ID: 18798714
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function.
    Kristof E; Szigeti G; Papp Z; Bodi A; Facsko A; Kovacs L; Papp JG; Kranias EG; Edes I
    Ann N Y Acad Sci; 1998 Sep; 853():316-9. PubMed ID: 10603968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.